HRP20191189T1 - Pirimido[4,5-b]indol derivati i njihova primjena u ekspanziji hematopoetskih matičnih stanica - Google Patents

Pirimido[4,5-b]indol derivati i njihova primjena u ekspanziji hematopoetskih matičnih stanica Download PDF

Info

Publication number
HRP20191189T1
HRP20191189T1 HRP20191189TT HRP20191189T HRP20191189T1 HR P20191189 T1 HRP20191189 T1 HR P20191189T1 HR P20191189T T HRP20191189T T HR P20191189TT HR P20191189 T HRP20191189 T HR P20191189T HR P20191189 T1 HRP20191189 T1 HR P20191189T1
Authority
HR
Croatia
Prior art keywords
optionally substituted
substituents
heterocyclyl
heteroaryl
aryl
Prior art date
Application number
HRP20191189TT
Other languages
English (en)
Inventor
Guy Sauvageau
Yves Gareau
Réjean RUEL
Stéphane GINGRAS
Iman FARES
Original Assignee
Université de Montréal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48872865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191189(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université de Montréal filed Critical Université de Montréal
Publication of HRP20191189T1 publication Critical patent/HRP20191189T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (15)

1. Spoj je formule IIA, formule IIB ili formule IIC ili njegova sol, Het je 3 do 7-člani heterocikl, po izboru supstituiran sa jednim ili više R1 ili RA; R5 i R6 su isti ili različiti i svako je nezavisno L, ili se udružuju zajedno sa C da se formira 5-člani prsten koji po izboru uključuje jedan ili više heteroatoma odabrana od N, O i S, po izboru prsten je supstituiran sa jednim ili više R1 ili RA; W je 74) -(N(R1)-L)n-N(R1)R1, Ili W je 1) -H, 2) -halogen, 3) -OR1, 4) -L-OH, 5) -L-OR1, 6) -SR1, 7) -CN, 8) -P(O)(OR1)(OR1), 9) -NHR1, 10) -N(R1)R1, 11) -L-NH2, 12) -L-NHR1, 13) -L-N(R1)R1, 14) -L-SR1, 15) -L-S(O)R1, 16) -L-S(O)2R1, 17) -L-P(O)(OR1)(OR1), 18) -C(O)OR1, 19) -C(O)NH2, 20) -C(O)NHR1, 21) -C(O)N(R1)R1, 22) -NHC(O)R1, 23) -NR1C(O)R1, 24) -NHC(O)OR1, 25) -NR1C(O)OR1, 26) -OC(O)NH2, 27) -OC(O)NHR1, 28) -OC(O)N(R1)R1, 29) -OC(O)R1, 30) -C(O)R1, 31) -NHC(O)NH2, 32) -NHC(O)NHR1, 33) -NHC(O)N(R1)R1, 34) -NR1C(O)NH2, 35) -NR1C(O)NHR1, 36) -NR1C(O)N(R1)R1, 37) -NHS(O)2R1, 38) -NR1S(O)2R1, 39) -S(O)2NH2, 40) -S(O)2NHR1, 41) -S(O)2N(R1)R1, 42) -S(O)R1, 43) -S(O)2R1, 44) -OS(O)2R1, 45) -S(O)2OR1, 46) -benzil po izboru supstituiran sa 1, 2 ili 3 RA ili R1 supstituenta, 47) -L-heteroaril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na heteroaril grupi, 48) -L-heterociklil po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na heterociklil grupi, 49) -L-aril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na aril grupi, 50) -L-NR1(R1), 51) -L-)2NR1, 52) -L-(N(R1)-L)n-N(R1)R1, 53) -L-(N(R1)-L)n - heteroaril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na heteroaril grupi, 54) -L-(N(R1)-L)n - heterociklil po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na heterociklil grupi, 55) -L-(N(R1)-L)n - aril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na aril grupi, 56) -O-L-N(R1)R1, 57) -O-L- heteroaril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na heteroaril grupi, 58) -O-L- heterociklil po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na heterociklil grupi, 59) -O-L- aril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na aril grupi, 60) -O-L)2-NR1, 61) -O-L-(N(R1)-L)n - N(R1)R1, 62) -O-L-(N(R1)-L)n - heteroaril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na heteroaril grupi, 63) -O-L-(N(R1)-L)n - heterociklil po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na heterociklil grupi, 64) -O-L-(N(R1)-L)n- aril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata, 65) -S-L- heteroaril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata, 66) -S-L- heterociklil po izboru supstituiran sa jednim ili više RA ili R1 supstituenata, 67) -S-L- aril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na aril grupi, 68) -S-L)2NR1, 69) -S-L-(N(R1)-L)n - N(R1)R1, 70) -S-L-(N(R1)-L)n - heteroaril po izboru supstituiran sa jednim ili više RA supstituenata, 71) -S-L-(N(R1)-L)n - heterociklil po izboru supstituiran sa jednim ili više RA supstituenata, 72) -S-L-(N(R1)-L)n - aril po izboru supstituiran sa jednim ili više RA supstituenata, 73) -NR1(R1), 75) -N(R1)L)2-NR1, 76) -(N(R1)-L)n - N(R1)RA, 77) -(N(R1)-L)n - heteroaril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata, 78) -(N(R1)-L)n - heterociklil po izboru supstituiran sa jednim ili više RA ili R1 supstituenata, 79) -(N(R1)-L)n - aril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata, 80) -heteroaril po izboru supstituiran sa jednim ili više RA supstituenata, ili 81) -aril po izboru supstituiran sa jednim ili više RA supstituenata, i gdje svaki supstituent je po izboru vezan za L grupu ukoliko nije već prisutan, i gdje kada su dva R1 supstituenta prisutna na istom atomu dušika, tada svaki R1 supstituent je nezavisno odabran sa liste R1 vrijednosti opisane kasnije, i gdje n je cijeli broj jednak sa bilo 0, 1, 2, 3, 4, ili 5, i gdje, kada (R1) i R1 su vezani za atom dušika, po izboru oni se udružuju zajedno sa atomom dušika da se formira 3 do 7-člani prsten koji po izboru uključuje jedan ili više drugih heteroatoma odabranih od N, O i S, po izboru prsten je supstituiran sa jednim ili više R1 ili RA; L je 4) -C3-7 cikloalkil ili 1) -C1-6 alkil, ili L je 2) -C2-6 alkenil, 3) -C2-6 alkinil, 5) -C3-7 cikloalkenil, 6) heterociklil, 7) -C1-6 alkil-C3-7 cikloalkil, 8) -C1-6 alkil-heterociklil, 9) aril, ili 10) heteroaril, i gdje alkil, alkenil, alkinil, cikloalkil, cikloalkenil, heterociklil, aril i heteroaril grupe su svaka nezavisno po izboru supstituirana sa jednim ili dva RA supstituenta; R1 je 1) -H, 2) -C1-6 alkil, 3) -C2-6 alkenil, 4) -C2-6 alkinil, 5) -C3-7 cikloalkil, 6) -C3-7 cikloalkenil, 7) -C1-5 perfluorovan, 8) -heterociklil, 9) -aril, 10) -heteroaril, 11) -benzil, ili 12) 5-[(3aS,4S,6aR)-2-oksoheksahidro-1H-tieno[3,4-d]imidazol-4-il]pentanoil, i gdje alkil, alkenil, alkinil, cikloalkenil, perfluorovan alkil, heterociklil, aril, heteroaril i benzil grupe su svaka nezavisno po izboru supstituirana sa 1, 2 ili 3 RA ili R1 supstituenta; R2 je 7) benzil po izboru supstituiran sa 1, 2 ili 3 RA ili R1 supstituenta; ili 1) -H, Ili R2 je 2) -C1-6 alkil, 3) -SR1, 4) -C(O)R1, 5) -S(O)R1, 6) -S(O)2R1, 8) -L-heteroaril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na heteroaril grupi, 9) -L-heterociklil po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na heterociklil grupi, 10) -L-aril po izboru supstituiran sa jednim ili više RA ili R1 supstituenata vezanih na jednoj ili i na L i na aril grupi, 11) -heteroaril po izboru supstituiran sa jednim ili više RA ili R1 supstituenta, ili 12) -aril po izboru supstituiran sa jednim ili više RA ili R1 supstituenta, i gdje svaki supstituent je po izboru vezan za L grupu ukoliko nije već prisutan; RA je 1) -halogen, 2) -CF3, 3) -OH, 4) -OR1, 5) -L-OH, 6) -L-OR1, 7) -OCF3, 8) -SH, 9) -SR1, 10) -CN, 11) -NO2, 12) -NH2, 13) -NHR1, 14) -NR1R1, 15) -L-NH2, 16) -L-NHR1, 17) -L-NR4R1, 18) -L-SR1, 19) -L-S(O)R1, 20) -L-S(O)2R1, 21) -C(O)OH, 22) -C(O)OR1, 23) -C(O)NH2, 24) -C(O)NHR1, 25) -C(O)N(R1)R1, 26) -NHC(O)R1, 27) -NR1C(O)R1, 28) -NHC(O)OR1, 29) -NR1C(O)OR1, 30) -OC(O)NH2, 31) -OC(O)NHR1, 32) -OC(O)N(R1)R1, 33) -OC(O)R1, 34) -C(O)R1, 35) -NHC(O)NH2, 36) -NHC(O)NHR1, 37) -NHC(O)N(R1)R1, 38) -NR1C(O)NH2, 39) -NR1C(O)NHR1, 40) -NR1C(O)N(R1)R1, 41) -NHS(O)2R1, 42) -NR1S(O)2R1, 43) -S(O)2NH2, 44) -S(O)2NHR1, 45) -S(O)2N(R1)R1, 46) -S(O)R1, 47) -S(O)2R1, 48) -OS(O)2R1, 49) -S(O)2OR1, 50) -benzil, 51) -N3, ili 52) -C(-N=N-)(CF3), i gdje benzil grupa je po izboru supstituirana sa 1, 2 ili 3 RA ili R1 supstituenta, pod uvjetom da Spoj formule IIA, formule IIB ili formule IIC je različit od
2. Spoj prema patentnom zahtjevu 1, gdje heteroatom je N u 5-članom prstenu formiranom pomoću R5 i R6 zajedno.
3. Spoj prema patentnom zahtjevu 1 ili 2, gdje navedeni spoj ima formulu IIC i R2 je benzil.
4. Spoj prema patentnom zahtjevu 1, gdje: u formuli IIA, je CO2Me i u formuli IIC, R5 i R6 se udružuju zajedno sa C da se formira 2-metil-2H-tetrazol-5-il; R2 je benzil, 3-tienilmetil ili 3-piridinil metil; i W je NH-L-N(R1)R1 gdje L je C2-4 alkil i R1 je C1-4 alkil ili (R1) i R1 se udružuju zajedno sa atomom dušika za koji su vezani da se formira 3 do 7-člani prsten, koji po izboru uključuje jedan ili više drugih heteroatoma odabranih od N, O i S, po izboru prsten je supstituiran sa jednim ili više R1 ili RA.
5. Spoj koje je:
Ili njegova sol.
6. Spoj prema patentnom zahtjevu 1 koje je ili farmaceutski prihvatljiva sol istog.
7. Spoj prema patentnom zahtjevu 1 gdje spoj je ili farmaceutski prihvatljiva sol istog.
8. Spoj prema patentnom zahtjevu 1 gdje spoj je ili farmaceutski prihvatljiva sol istog.
9. Metoda povećanja matičnih i progenitorskih stanica, metoda koja obuhvata: kultiviranje in vitro ili ex vivo polazne stanice populacije koja sadrži hematopoetske matične stanice sa agensom koji sadrži spoj ili njegovu sol kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 8, po izboru zajedno sa najmanje jednim faktorom za staničnu ekspanziju koji je biološki ili druga mala molekula.
10. Metoda iz patentnog zahtjeva 9, u kojoj polazna stanična populacija uključuje CD34+ stanice prikupljene iz mobilizirane periferne krvi (mPB), koštane srži (BM) ili krvi pupčane vrpce (UCB).
11. Farmaceutska kompozicija koja sadrži spoj kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 8 ili njegovu sol, i farmaceutski prihvatljiv nosač.
12. Spoj kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 8 ili njegova sol za primjenu u liječenju hematopoetskog poremećaja/maligniteta, autoimune bolesti i/ili nasljedne imunodeficijentne bolesti kod subjekta.
13. Spoj kao što je definirano u patentnom zahtjevu 12 gdje navedeni hematopoetski poremećaj/malignitet, autoimuna bolest i/ili nasljedna imunodeficijentna bolest obuhvaćaju stanja insuficijencije koštane srži, razne kongenitalne bolesti općeg značaja (npr. anemiju srpastih stanica i talasemiju), lupus, akutnu mijeloidnu leukemiju, akutnu limfoblastnu leukemiju, kroničnu mijeloidnu leukemiju, kroničnu limfocitnu leukemiju, mijeloproliferativne poremećaje, mijelodisplastične sindrome, multipli mijelom, ne-Hodgkin-ov limfom, Hodgkin-ovu bolest, aplastičnu anemiju, čistu aplaziju eritrocita, hemoglobinuriju, Fanconi anemiju, talasemiju, anemiju srpastih stanica, Wiskott-Aldrich-ov sindrom, urođene greške u metabolizmu (kao što je Gaucher-ova bolest).
14. Farmaceutska kompozicija prema patentnom zahtjevu 11, koja je pogodna za intravensku infuziju.
15. Komplet za primjenu u ekspandiranju hematopoetskih matičnih stanica, koji sadrži spoj kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 8, ili njegovu sol, i uputstva za primjenu, po izboru, komplet sadrži najmanje jedan faktor za ekspanziju stanica koji je biološki ili druga mala molekula.
HRP20191189TT 2012-01-27 2019-07-02 Pirimido[4,5-b]indol derivati i njihova primjena u ekspanziji hematopoetskih matičnih stanica HRP20191189T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591521P 2012-01-27 2012-01-27
PCT/CA2013/050052 WO2013110198A1 (en) 2012-01-27 2013-01-25 Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
EP13740815.9A EP2807165B1 (en) 2012-01-27 2013-01-25 Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells

Publications (1)

Publication Number Publication Date
HRP20191189T1 true HRP20191189T1 (hr) 2019-10-04

Family

ID=48872865

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191189TT HRP20191189T1 (hr) 2012-01-27 2019-07-02 Pirimido[4,5-b]indol derivati i njihova primjena u ekspanziji hematopoetskih matičnih stanica

Country Status (24)

Country Link
US (3) US9409906B2 (hr)
EP (1) EP2807165B1 (hr)
JP (1) JP6250556B2 (hr)
KR (1) KR102098122B1 (hr)
CN (1) CN104144931B (hr)
AU (1) AU2013212457B2 (hr)
BR (1) BR112014018524B1 (hr)
CA (1) CA2862140C (hr)
CY (1) CY1121799T1 (hr)
DK (1) DK2807165T3 (hr)
ES (1) ES2733946T3 (hr)
HK (1) HK1203945A1 (hr)
HR (1) HRP20191189T1 (hr)
HU (1) HUE044070T4 (hr)
IL (1) IL233587B (hr)
LT (1) LT2807165T (hr)
NZ (1) NZ627188A (hr)
PL (1) PL2807165T3 (hr)
PT (1) PT2807165T (hr)
RS (1) RS59002B1 (hr)
SG (1) SG11201404241SA (hr)
SI (1) SI2807165T1 (hr)
TR (1) TR201909582T4 (hr)
WO (1) WO2013110198A1 (hr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404241SA (en) 2012-01-27 2014-08-28 Univ Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
AU2014249192B2 (en) 2013-03-11 2017-12-21 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
CA2848575C (en) 2013-05-17 2021-01-26 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
JP2017511801A (ja) * 2014-02-28 2017-04-27 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体
EP3134409B1 (en) * 2014-04-22 2020-02-12 Université de Montréal Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
US10273503B2 (en) * 2014-09-18 2019-04-30 Universite De Montreal Compounds and methods for enhancing viral gene transfer to human hematopoietic cells
WO2016109661A1 (en) * 2014-12-31 2016-07-07 Anthrogenesis Corporation Natural killer cells and uses thereof
JP6734283B2 (ja) * 2015-01-21 2020-08-05 フレッド ハッチンソン キャンサー リサーチ センター 遺伝子治療用ポイントオブケア及び／又はポータブルプラットフォーム
JP6954844B2 (ja) * 2015-06-05 2021-10-27 エマ−ケベック 造血幹細胞を培養するため及び／又は造血幹細胞を前駆体へ分化させるための方法及びその使用
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN105316293A (zh) * 2015-09-23 2016-02-10 广东颐养抗衰老研究院 一种体外获得造血干/祖细胞的方法
BR112018007538A2 (pt) * 2015-10-15 2018-10-23 Celularity Inc células exterminadoras naturais e células ilc3 e usos das mesmas
WO2017115268A1 (en) * 2015-12-28 2017-07-06 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CA3023239A1 (en) * 2016-05-07 2017-11-16 Celularity Inc. Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
AU2017325511B2 (en) * 2016-08-18 2021-12-09 National University Of Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
CN109844126A (zh) 2016-09-28 2019-06-04 诺华股份有限公司 基于多孔膜的大分子递送系统
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
JP2020537541A (ja) 2017-09-29 2020-12-24 インテリア セラピューティクス，インコーポレーテッド 脂質ナノ粒子を用いるインビトロでのｍｒｎａの送達方法
EP3704126A4 (en) * 2017-11-03 2020-12-09 Université de Montréal COMPOUNDS AND THEIR USE IN THE EXPANSION OF STEM CELLS AND / OR PROGENITOR CELLS
CN111902411A (zh) * 2018-01-03 2020-11-06 美真达治疗公司 用于扩增造血干细胞和祖细胞以及治疗遗传性代谢紊乱的组合物和方法
WO2019161494A1 (en) * 2018-02-20 2019-08-29 Universite De Montreal Expansion of nk and dc cells in vivo mediating immune response
LT3873903T (lt) * 2018-10-31 2024-05-10 Gilead Sciences, Inc. Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
KR102329235B1 (ko) * 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
CN115176005A (zh) 2019-12-18 2022-10-11 诺华股份有限公司 用于治疗血红蛋白病的组合物和方法
CA3164153A1 (en) * 2019-12-18 2021-06-24 Universite De Montreal Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds
US20230094952A1 (en) 2019-12-26 2023-03-30 Sumitomo Pharma Co., Ltd. Method for Culturing Hematopoietic Stem Cells
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2021256977A1 (en) * 2020-06-15 2021-12-23 Subramaniam Agatheeswaran Novel methods and compounds for protein degradation
IL299456A (en) * 2020-06-25 2023-02-01 Angiocrine Bioscience Inc Endothelial cells to reduce chemotherapy-induced toxicity
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRAL BODY WITH CRYOPROTECTIVE USING VACUUM-ASSISTED DIFFUSION
AU2021360590A1 (en) 2020-10-14 2023-06-15 Ossium Health, Inc. Systems and methods for extraction and cryopreservation of bone marrow
EP4262831A1 (en) 2020-12-18 2023-10-25 Ossium Health, Inc. Methods of cell therapies
WO2022230793A1 (ja) * 2021-04-26 2022-11-03 住友ファーマ株式会社 オキセピン誘導体
WO2022232839A1 (en) 2021-04-30 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improved production of primary cd34+ cells
WO2022269518A2 (en) 2021-06-23 2022-12-29 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
GB202111169D0 (en) 2021-08-03 2021-09-15 Adaptimmune Ltd Methods of T cell production
CN114736862B (zh) * 2022-05-18 2024-05-28 诺航生物技术研究院徐州有限公司 一种造血干细胞培养基和造血干细胞的体外扩增方法
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
US11964981B1 (en) 2023-09-18 2024-04-23 King Faisal University Substituted pyrimido[4,5-b]indoles as CK2 inhibitors
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1262864A (en) 1968-03-29 1972-02-09 Glaxo Lab Ltd Diazacarbazoles
ES2150941T3 (es) 1992-04-03 2000-12-16 Upjohn Co Aminas biciclicas-heterociclicas eficaces farmaceuticamente.
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DK0836605T3 (da) * 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
SI0964865T1 (en) 1997-01-08 2003-08-31 Pharmacia & Upjohn Company Pharmaceutically active tricyclic amines
EP1133291B1 (en) 1998-11-17 2006-01-11 Smithkline Beecham Corporation Cyclic polyamines for treating thrombocytopenia
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
EP1189609A4 (en) 1999-05-03 2002-10-30 Smithkline Beecham Corp CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA
ATE315934T1 (de) 1999-09-10 2006-02-15 Smithkline Beecham Corp Thrombopoietin-mimetika
WO2001021180A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
AU1462201A (en) 1999-11-05 2001-06-06 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
AU2079901A (en) 1999-12-06 2001-06-12 Smithkline Beecham Corporation Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
CA2436288A1 (en) 2000-12-19 2002-06-27 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
AU2002309703A1 (en) * 2001-05-09 2002-11-18 The University Of Louisville Research Foundation, Inc. Hematopoietic stem cell chimerism to treat autoimmune disease
WO2003037898A1 (en) 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
JP4562523B2 (ja) 2002-06-06 2010-10-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポエチン疑似体
US20060084682A1 (en) 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
WO2004058764A1 (en) 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
AU2004234627A1 (en) 2003-05-02 2004-11-11 Insception Bioscience, Inc. Apparatus and methods for amplification of blood stem cell numbers
PT1678166E (pt) 2003-10-14 2009-10-30 Supergen Inc Inibidores de proteína-quinase
BRPI0609956A2 (pt) 2005-04-28 2010-05-18 Supergen Inc inibidores de proteìna quinase
MX2008000462A (es) 2005-07-14 2008-03-10 Irm Llc Compuestos heterotetraciclicos como mimeticos de tpo.
EP1749822B1 (en) * 2005-08-05 2008-10-15 Hybrigenics S.A. Novel cysteine protease inhibitors and their therapeutic applications
KR20080035700A (ko) 2005-08-15 2008-04-23 아이알엠 엘엘씨 Ｔｐｏ 모방체로서의 화합물 및 조성물
MX2008015975A (es) 2006-06-14 2009-03-26 Chugai Pharmaceutical Co Ltd Agentes para promocionar el crecimiento de celulas de vastago hematopoyeticas.
JP2008050355A (ja) 2006-08-21 2008-03-06 Eisai R & D Management Co Ltd 造血幹細胞を増殖、分化および／または循環系内に動員させる医薬組成物および方法
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
US20080207632A1 (en) 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
EP2155862A2 (en) 2007-05-04 2010-02-24 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
JP2010193879A (ja) 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
WO2011056739A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Compounds and methods
MX345780B (es) * 2011-03-15 2017-02-15 Trius Therapeutics Inc Inhibidores triciclicos de girasa.
SG11201404241SA (en) 2012-01-27 2014-08-28 Univ Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells

Also Published As

Publication number Publication date
EP2807165A4 (en) 2015-08-26
BR112014018524A8 (pt) 2017-07-11
AU2013212457B2 (en) 2017-02-16
HUE044070T4 (hu) 2019-12-30
US20170334904A1 (en) 2017-11-23
EP2807165A1 (en) 2014-12-03
CN104144931B (zh) 2018-04-10
CA2862140A1 (en) 2013-08-01
EP2807165B1 (en) 2019-05-15
BR112014018524B1 (pt) 2023-03-28
SI2807165T1 (sl) 2019-08-30
NZ627188A (en) 2015-12-24
PL2807165T3 (pl) 2019-09-30
BR112014018524A2 (pt) 2021-06-08
KR102098122B1 (ko) 2020-04-07
US20150011543A1 (en) 2015-01-08
KR20140121454A (ko) 2014-10-15
RS59002B1 (sr) 2019-08-30
JP6250556B2 (ja) 2017-12-20
HK1203945A1 (en) 2015-11-06
SG11201404241SA (en) 2014-08-28
IL233587B (en) 2019-11-28
JP2015504902A (ja) 2015-02-16
CN104144931A (zh) 2014-11-12
HUE044070T2 (hu) 2019-09-30
IL233587A0 (en) 2014-08-31
AU2013212457A1 (en) 2014-09-18
ES2733946T3 (es) 2019-12-03
CA2862140C (en) 2020-04-21
US9409906B2 (en) 2016-08-09
TR201909582T4 (tr) 2019-07-22
DK2807165T3 (da) 2019-07-15
CY1121799T1 (el) 2020-07-31
WO2013110198A1 (en) 2013-08-01
US10336747B2 (en) 2019-07-02
PT2807165T (pt) 2019-07-12
LT2807165T (lt) 2019-07-25
US20160222017A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
HRP20191189T1 (hr) Pirimido[4,5-b]indol derivati i njihova primjena u ekspanziji hematopoetskih matičnih stanica
JP2015504902A5 (hr)
JP2017513897A5 (hr)
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
JP2018528946A5 (hr)
RS54785B1 (sr) Pirolopirazin-spirociklični piperidin amidi kao modulatori jonskih kanala
RS54723B1 (en) CONDENSED IMIDASOL DERIVATIVES USEFUL AS IDO INHIBITORS
JP2013523614A5 (hr)
HRP20230909T1 (hr) Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
JP2019532928A5 (hr)
JP2014502266A5 (hr)
SI2704721T1 (en) ACTIVATORS PIANO KINASE FOR USE IN THERAPY
EP3134409A1 (en) Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
JP2015504081A5 (hr)
SI2928476T1 (en) COMPONENTS, INSTALLATIONS AND PROCEDURES OF THE APPLICATION OF E-SELECTINE OF ANTAGONISTS FOR THE MOBILIZATION OF HEMATOPOETIC CELLS
US9801863B2 (en) Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
JP2014519524A5 (hr)
NZ631523A (en) Compounds for the treatment of mtor pathway related diseases
RS52838B (en) PHENOXIMETHYL HETEROCYCLIC COMPOUNDS
PH12015502684A1 (en) New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof
HRP20192121T1 (hr) Derivati pirido-oksazinona kao tnap inhibitori
MX344474B (es) Nuevos derivados de furanona.
PH12019500742A1 (en) Urea derivative